![David Elsley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Elsley
Fondatore presso CARDIOL THERAPEUTICS INC.
Patrimonio netto: 2 M $ in data 30/06/2024
Posizioni attive di David Elsley
Società | Posizione | Inizio | Fine |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Direttore/Membro del Consiglio | 19/01/2017 | - |
Amministratore Delegato | 19/01/2017 | - | |
Fondatore | 19/01/2017 | - | |
Presidente | 19/01/2017 | - |
Storia della carriera di David Elsley
Precedenti posizioni note di David Elsley
Società | Posizione | Inizio | Fine |
---|---|---|---|
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Direttore/Membro del Consiglio | 01/01/1990 | 23/10/2009 |
Fondatore | 01/01/1990 | 23/10/2009 |
Formazione di David Elsley
Richard Ivey School of Business | Masters Business Admin |
University of Western Ontario | Masters Business Admin |
Statistiche
Distribuzione geografica
Canada | 5 |
Posizioni
Director/Board Member | 2 |
Founder | 2 |
Masters Business Admin | 2 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Aziende private | 1 |
---|---|
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Borsa valori
- Insiders
- David Elsley
- Esperienza